Single-chamber Versus Dual-chamber Implantable Cardioverter Defibrillators: Do We Need Physiologic Pacing in The Course? by Budeus, Marco et al.
 
www.ipej.org 153
Original Article
Single-chamber   Versus   Dual-chamber   Implantable 
Cardioverter Defibrillators: Do We Need Physiologic Pacing 
in The Course?
Marco Budeus, Thomas Buck, Heinrich Wieneke, Raimund Erbel, Stefan Sack                           
Department of Cardiology, West-German Heart Centre, University of Duisburg-Essen, Germany 
Address for correspondence: Marco Budeus, MD, Department of Cardiology, West-German 
Heart Centre, University of Duisburg-Essen, Hufelandstr. 55, D-45122 Essen, Germany. E-mail: 
marco.budeus@medizin.uni-essen.de
Abstract  
Background:  Many patients with ICD receive different antiarrhythmic drugs (e.g. sotalol, 
amiodarone, β-blockers) because of ventricular or atrial tachycardias. These drugs can cause 
AV-block or chronotropic incompetence resulting in a higher percentage of ventricular pacing.
Methods: We analyzed in a retrospective study the impact of DDD(R) versus VVI(R) mode on 
subjective (NYHA classification) and objective parameters [brain natriuretic peptide (BNP), 6 
minute walk test, echocardiography] in 12 of 120 patients (age 60.2 ± 11.2 years; 10 males, 2 
females) who needed an upgrading of a single to a dual chamber ICD. The ICD had to be 
upgraded because of chronotropic incompetence in all patients with signs of progressing heart 
failure. Data were collected in VVI(R)-pacing and after 6 and 12 months in DDD(R)-pacing 
with   a   long   AV-interval   and   AV   hysteresis   to   reduce   ventricular   pacing.  
Results:  The 6 minute walk test (392.4 ± 91.4 vs. 324.6 ± 93.3 m, P < 0.001), NYHA-
classification (1.4 ± 0.3 vs. 2.6 ± 0.8, P < 0.0001), BNP (234.1 ± 73.5 vs. 410.4 ± 297.0 pg/ml, P 
< 0.001), left ventricular ejection fraction (49.8 ± 9.6 vs. 36.5 ± 10.9 %, P < 0.0001) and A-wave 
(73.6 ± 13.7 vs. 41.0 ± 14.0 cm/sec, P < 0.0001) improved with DDD(R)-pacing after 12 
months. The ventricular pacing decreased (84.2 ± 18.1 vs. 1.1 ± 1.7 %, P < 0.0001) after 12 
months by DDD(R)-pacing with long AV-interval (220.0 ± 10.4 ms) and AV hysteresis.  
Conclusion:  Our data show a superiority of DDD(R) mode versus VVI(R) mode regarding 
subjective and objective parameters as NYHA-classification, BNP, 6 minute walk test, left 
ventricular ejection fraction and left ventricular endsystolic volume after 12 months. The 
improvements seem to depend on the reduction of ventricular pacing with advanced atrial 
contraction.   But   only   a   small   number   of   patients   needed   the   upgradation.  
Key Words: brain natriuretic peptide; 6 minute walk test; single chamber ICD; dual chamber 
ICD  
Introduction
            The main function of implantable cardioverter defibrillator (ICD) therapy is to preserve 
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life by terminating life-threatening tachycardias like ventricular fibrillation (VF) and ventricular 
tachycardia (VT). Many studies showed the benefit for ICD in primary and secondary prevention 
of sudden cardiac death in patients with different cardiac diseases1-9. In addition ICD is superior 
to antiarrhythmic therapy for preventing sudden cardiac death1,3,5,7,8. One side effect of ICD 
therapy is the painful shock needed to terminate the life-threatening tachycardias. Different 
studies showed a reduction of the ICD therapy by an additional antiarrhythmic therapy10-14. 
               Patients having a reduced left ventricular function had worsening of their cardiac 
function with higher percentage of ventricular pacing15-18). Physiologic pacing or no pacing has 
to be preferred in patients with lower cardiac function and ICD implantation because of 
worsening of their cardiac function by ventricular pacing. But the accompanying antiarrhythmic 
therapy (e.g. sotalol, amiodarone, β-blockers) can cause an AV-block or a chronotropic 
incompetence resulting in a higher percentage of ventricular pacing. Therefore patients with 
accompanying   antiarrhythmic   therapy   for   preventing   painful   shocks   should   be   paced 
physiologically   or   not   paced   at   all   to   prevent   a   worsening   of   their   cardiac   function.
             The aim of the retrospective investigation was to compare DDD(R) versus VVI(R) 
pacing on subjective (NYHA classification) and objective [brain natriuretic peptide (BNP), 6 
minute walk test, echocardiography] parameters in patients after a required upgrading of a single 
to a dual chamber ICD for physiologic pacing.                                                                         
Methods
            We examined 124 patients with different heart diseases and implanted single chamber 
ICD since 1998 in our study. The ICD was implanted because of a VT (42 patients), VF (59 
patients) or a primary indication (23 patients) due to the MADIT II criteria4. The ICD had to be 
implanted at least six months before the inclusion into our study without a pacing indication at 
the time of the implant. The ICD was programmed to 50 ppm in the VVI mode at the beginning 
of our retrospective study. We used the interrogable data of the ICD to look for the percentage of 
ventricular   pacing   every   three   months.                                          
               We monitored every patient who had an increase of NYHA classification for the 
indication of upgrading the ICD since 2000 with echocardiography and ECG. The indication for 
a   resynchronization   therapy   was   an   intrinsic   QRS   ≥   120ms   and   an   asynchrony   on 
echocardiography.  
            The indication for upgrading to a DDD-ICD was a chronotropic incompetence and a high 
percentage   of   ventricular   pacing   (>70%)   corresponding   with   an   increase   of   NYHA 
classification. Patients (12 patients) with a chronotropic incompetence and >70% ventricular 
pacing were programmed to VVIR pacing. When the patients (12 patients) were still in the 
increased NYHA classification the ICD was upgraded to a DDD-ICD.                            
               Patients were excluded in case of an indication for resynchronization therapy (16 
patients), second (no patient) or third (no patient) degree AV block, an inability to walk (no 
patient) or a life expectancy below 6 months (no patient). The inclusion criterion was an 
upgradation from single to dual-chamber ICD because of the indication of pacing like 
chronotropic incompetence. In addition the medication had to be unchanged for 3 months. 
            Demographic data, medications and medical history were gathered by a patient interview 
and the review of their medical record at baseline and after six and twelve months. The DDD-
ICD was programmed to 50 ppm with rate-responsive pacing, an AV-interval which was 20 ms 
longer than the intrinsic AV-interval and an AV hysteresis for reducing ventricular pacing 
(DDDR-50; n = 12). The interrogable data of the ICD were analysed for the percentage of 
ventricular   pacing   every   three   months.                                                              
            The subjective (NYHA classification) and objective parameters [brain natriuretic peptide 
(BNP), 6 minute walk test, echocardiography] were evaluated at baseline (within one week 
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before upgrading to a dual-chamber ICD) after six and twelve months in DDD(R)-pacing which 
were routine clinical practice in our clinic. The 6-minute walk tests were performed randomly 
during working hours at baseline, after 6 and 12 months. Patients were instructed to walk as far 
as possible within 6 minutes with a running wheel, with standardized encouragement and breaks 
when necessary. At the time of echocardiographic evaluation the physician was blinded for the 
ICD pacing mode. BNP measurement (Triage Meter Plus®, Biosite GmbH, Willich, Germany) 
was performed randomly during working hours at baseline, after 6 and 12 months.              
Echocardiography
            The physicians were blinded to the mode of the ICD during the study. Biplanar left 
ventricular end-diastolic and end-systolic cavity volumes were calculated using Simpson's rule19 
from paired apical four-chamber and apical long-axis echocardiographic images of a minimum 
of five cardiac cycles; mean values of each variable were estimated. Biplanar ejection fractions 
were calculated as End-diastolic volume - End systolic volume / End-diastolic volume x 100%22. 
Pulsed Doppler analysis of mitral inflow included measurements for maximal E and A 
velocities, E/A ratio. The mean of five measurements was taken as the result. Doppler colour 
flow mapping was used to identify the presence or absence of mitral valve regurgitation. Gain 
settings were optimized by reducing the gain to the point where background noise disappeared. 
The direction of the MR jet was assessed from both parasternal and apical views, and the area of 
the largest clearly definable colour flow disturbance was traced in each view as an index of the 
severity of mitral valve regurgitation21. Left atrial size was measured by M-mode and two-
dimensional echocardiography in all patients with VVI(R) pacing and 6 months after DDD(R) 
pacing using the Phillips ultrasonic device (3.5 MHz; model Sonos 5500, Philips Medical 
System,   Andover,   Massachusetts,   USA).                                              
Statistics
              All data are presented as mean values ± standard deviation and as percentages for 
categorical variables. Data sets were tested with regard to normal distribution. For comparison 
between baseline and 6 months follow-up, the two-sided Friedman ANOVA test was used for 
NYHA classification, echocardiographic parameters, 6-minute walk test, BNP and ventricular 
pacing. A measurement of the linear association between two variables was evaluated using 
Pearson correlation coefficient. A multivariate Cox regression analysis was performed on 
variables found to be significant predictors (p < 0.1) with an univariate analysis for upgrading of 
the ICD. All statistical tests were two-tailed. A P value < 0.05 was considered as statistically 
significant. SPSS 12.0 for Windows was used as the statistical package.                                 
Results
            The ICD had to be upgraded because of chronotropic incompetence in 12 patients. These 
patients had a higher incidence of amiodarone therapy (Table 1). Defibrillator systems were 
manufactured by Biotronik GmbH & Co (Berlin, Germany), Guidant Corp. (St. Paul, MN), 
Medtronic Inc. (Minneapolis, MN), (alphabetical order). The ICD was implanted because of a 
VT (8 patients), VF (2 patients) or a primary indication (2 patients) due to the MADIT II 
criteria4 without indication for a DDD-ICD at implantation. The clinical characteristics of the 
patients are shown in Table 1. 
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Table 1: Patients characteristics
            The patients received an additional antiarrhythmic therapy in the follow-up because of 
paroxysmal atrial fibrillation with inappropriate shocks (3 patients) and repeated VTs with 
appropriate shocks (9 patients). Paroxysmal atrial fibrillation was no longer observed during the 
further follow-up after the additional antiarrhythmic therapy with amiodarone in the three 
patients with inappropriate shocks.                                                                           
            The increase of NYHA classification occurred 11.6 ± 2.3 months after receiving an 
additional antiarrhythmic therapy caused by a sinus bradycardia and programming rate-
responsive pacing function. The heart rate decreased from 59.0 ± 12.7 to 31.2 ± 5.2 (P < 0.0001) 
due to the antiarrhythmic therapy with amiodarone. The ICD had to be upgraded after a mean 
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follow-up of 25.8 ± 13.7 months after ICD implant and nearly 85% ventricular pacing in all 
patients. The programmed AV-interval was 220.0 ± 10.4 ms.                                           
            A retrograde ventricular-atrial conduction was excluded with the dual chamber ICD as 
reason for the impaired effect of VVIR-and VVI-pacing.                                                         
Subjective   parameters                                                                    
            The NYHA classification increased significantly from 1.5 ± 0.4 at implant to 2.6 ± 0.8 
nearly 12 months with >70% ventricular pacing after receiving amiodarone therapy. After 6 
months (1.6 ± 0.6 vs. 2.6 ± 0.8; P < 0.0001) and after 12 months (1.4 ± 0.3 vs. 2.6 ± 0.8, P < 
0.0001) with DDD(R) pacing NYHA classification decreased significantly.                        
Objective   parameters                                                                    
            After 6 months with DDD(R) pacing the BNP (410.4 ± 297.0 vs. 312.3 ± 213.6 pg/ml, P 
< 0.014) and 6 minute walk test (324.6 ± 93.3 vs. 374.7 ± 113.2 m, P < 0.013) improved in 
comparison to VVI(R) pacing. The 6-minute walk test (392.4 ± 91.4 vs. 324.6 ± 93.3 m, P < 
0.001), and BNP (234.1 ± 73.5 vs. 410.4 ± 297.0 pg/ml, P < 0.001) improved further after 12 
months.  
            The left ventricular endsystolic volume, left ventricular ejection fraction, left atrial size 
(and A-wave also improved significantly after 6 and 12 months with DDD(R) pacing (Table 2). 
The ventricular pacing was significantly reduced from 84.2 ± 18.1% to 1.1 ± 1.7  % (P < 0.0001) 
after 12 months with DDD(R) pacing. During the study the diuretic therapy was reduced in 8 
(75%) patients. This reduction included a reduction of furosemide (67.5 ± 30.1 vs. 40.0  ± 28.9 
mg, p < 0.054) and spironolactone (65.6 ± 22.9 vs. 37.5 ± 24.9 mg, p < 0.018). In the other four 
patients the medication was unchanged.   
Table 2: Comparison of echocardiographic results 
# = p < 0.001 in comparison to VVI(R)-pacing, * = p < 0.082 in comparison to VVI(R)-pacing, ° 
= p < 0.037 in comparison to VVI(R)-pacing, ¹ = p < 0.005 in comparison to VVI(R)-pacing, ² = 
p < 0.025 in comparison to VVI(R)-pacing, ³ = p < 0.0001 in comparison to VVI(R)-pacing, § = 
p < 0.011 in comparison to VVI(R)-pacing, $ = p < 0.05 in comparison to VVI(R)-pacing
Correlation
               We observed positive correlations between the reduction of ventricular pacing and 
improvement at the 6 minute walk test (r = 0.84, P < 0.001), NYHA classification (r = 0.79, P < 
0.001), the improvement of the BNP (r = 0.62, P < 0.031), the  left ventricular endsystolic 
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volume (r = 0.69, P < 0.019) and left ventricular ejection fraction (r = 0.92, P < 0.001).  
            In the multivariate regression analysis amiodarone treatment (odds ratio 31.6; 95% Cl 
4.26-122.05; p < 0.0001) and a ventricular pacing > 10% (odds ratio 129.7; 95% Cl 19.28-
315.73; p < 0.0001) were independent parameters for chronotropic incompetence corresponding 
with the upgrading to a DDD-ICD.                                                                          
Discussion
               In the present study we observed a significant improvement of subjective (NYHA 
classification) and objective (BNP, 6 minute walk test, echocardiography) parameters after 12 
months in DDD(R)-pacing compared with VVI(R)/VVI-pacing. The improvements correlated 
with a reduction of ventricular pacing. The additional implantation of an atrial lead and a 
programmed long AV-interval and AV hysteresis caused a reduction of ventricular pacing. We 
believe that the improvement was caused by atrioventricular synchrony and a larger part by  
reduction of ventricular pacing.                                                                                   
Comparison of VVI vs DDD pacing
            All patients  received a single chamber ICD for primary or secondary prevention of 
sudden cardiac death. The ICD had to be upgraded because of nearly 100% ventricular pacing 
corresponding with an increase of NYHA classification in our study. Former studies also 
observed an unanticipated necessity of pacing during the follow-up22-24. We showed an 
improved of NYHA-classification, BNP, 6 minute walk test, left ventricular ejection fraction and 
left ventricular endsystolic volume after 6 and 12 months with DDD(R)-pacing compared with 
VVI(R)-pacing.   The   improvements   were   significantly   correlated   with   the   reduction   of 
ventricular pacing. On the other side left atrial contraction was improved with physiologic 
pacing which became apparent by an increased A wave and the reduction of left atrial size. 
            The DAVID Trial confirmed the disadvantage of DDD(R)-pacing regarding a higher 
mortality and hospitalization for congestive heart failure whether ventricular pacing was  
necessary or not15. Because of the high incidence of ventricular pacing (55.7%) the left 
ventricular function worsened in the DAVID Trail due to programmed rate-responsive pacing at 
70/min   for   DDD   pacing15-18.                                                          
            In our study the improvements were achieved by a reduction of ventricular pacing. The 
histological alterations25,26 as a result of ventricular pacing were shown by myofibril disarray25,26 
followed by an impaired cardiac function15-18.                                                                         
Echocardiography
               The advantage of physiologic pacing was shown by different echocardiographic 
parameters. By means of synchrony of atrial and ventricular contraction a reduction of left 
ventricular endsystolic volume and left atrial size was accomplished.27 In addition the increase of 
the A wave suggested an improved left atrial contraction with physiologic pacing28,29. As a result 
of these improvements we observed an increase of the left ventricular ejection fraction like 
former   studies27-31.                                                              
            VVI pacing results in an impairment of the left ventricular function because of a loss of 
atrioventricular synchrony in patients with heart failure27,29,31 or by the pacemaker syndrome32. 
The loss of the atrioventricular synchrony is reversible in time due to physiologic pacing28. 
These parameters can be evaluated by echocardiography, which is an appropriate examination 
for the course of patients with pacemaker or ICD.                                                             
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Limitation
        The examination of a small study sample reduced the statistical significance of our results. 
In addition this was a short-term observational study and long-term outcomes are unknown in 
our trial. But similar results can be found in former studies with larger patients sample size15-
18,22-24,27-31.   The   influence   of   DDD(R)   pacing   on   the   incidence   of   atrial   or   ventricular 
tachyarrhythmias can not be estimated because the observation period between DDD(R) and 
VVI(R) pacing was too short. We could not fully achieve the blinding of the echocardiographer 
because the additional lead was visible in the right atrium and the difference between VVI 
pacing and AV synchrony was also apparent.                                                                                     
Conclusions
            The results of our study suggest that physiologic pacing improved subjective (NYHA 
classification) and objective (BNP, 6 minute walk test, echocardiography) parameters of patients 
with a new pacing indication. Physiologic pacing improves atrial and ventricular function in 
comparison to VVI(R) pacing. The reduction of ventricular pacing was the reason for these 
improvements.   Even   though   the   attention   has   been   directed   towards   the   cardiac 
resynchronization therapy for the improvement of heart failure we could achieve a significant 
enhancement of heart failure due to a reduction of ventricular pacing with increased physiologic 
pacing with a long AV-interval. In addition the indication for upgrading to a dual chamber ICD 
was accomplished in a small group of patients (10%). Thus in the most cases the implantation of 
a single chamber ICD was adequate. But this problem is going to accompany the clinical work. 
Amiodarone seems to be the risk factor for the upgrading of the ICD according to high incidence 
of ventricular pacing because of its antitachycardia effect.                                    
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